CCR5‐Delta32: implications in SLE development

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with strong genetic and environmental components. Previous studies have shown increased levels of several chemokines in active SLE. C‐C chemokine receptor type 5 (CCR5) is involved in the recruitment of inflammatory cells into tissues, and mechanisms modulating CCR5 expression and function may interfere in SLE development, influencing the clinical course of the disease. The aim of this study was to evaluate the possible association between the CCR5∆32 base‐pair deletion polymorphism and SLE disease in a group of Portuguese patients. A total of 219 patients with SLE and 205 healthy individuals were studied. The frequency of CCR5/∆32 heterozygotes was lower in patients with SLE than in controls (8% vs. 15% OR = 0.5162; P = 0.0319), suggesting a protective association between CCR5∆32 allele and SLE. These results highlight the protective role of Th1 cells that express CCR5 in SLE pathogenesis.

[1]  Jeremy MG Taylor,et al.  Resistance to HIV‐1 Infection , 1994 .

[2]  B. Bresnihan,et al.  CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial , 2010, Annals of the rheumatic diseases.

[3]  B. Tsao.  An update on genetic studies of systemic lupus erythematosus , 2002, Current rheumatology reports.

[4]  J. Rovensky,et al.  CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjögren's syndrome. , 2002, Clinical and experimental rheumatology.

[5]  C. Winkler,et al.  Population Survey of CCR5 &Dgr;32, CCR5 m303, CCR2b 64I, and SDF1 3´A Allele Frequencies in Indigenous Chinese Healthy Individuals, and in HIV-1-Infected and HIV-1-Uninfected Individuals in HIV-1 Risk Groups , 2003, Journal of acquired immune deficiency syndromes.

[6]  F. Baroody,et al.  Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells. , 2001, Journal of immunology.

[7]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[8]  J. Al-Saleh,et al.  The role of T helper cell subsets in pathogenesis of Systemic Lupus Erythematosus and their relation to disease activity. , 2006, Egyptian Journal of Immunology.

[9]  Is the CCR5 Delta 32 Mutation Associated with Immune System-Related Diseases? , 2013 .

[10]  Yu-Mei Li,et al.  mRNA expression of chemokine receptors on peripheral blood mononuclear cells and correlation with clinical features in systemic lupus erythematosus patients. , 2010, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[11]  T. Ninomiya,et al.  Predominance of Th1 immune response in diffuse proliferative lupus nephritis. , 2001, Arthritis and rheumatism.

[12]  M. Akahoshi,et al.  Th1/Th2 balance of SLE patients with lupus nephritis. , 2006, Rinsho byori. The Japanese journal of clinical pathology.

[13]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.

[14]  L. Vilá,et al.  Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. , 2007, Clinical rheumatology.

[15]  J. Sodroski,et al.  CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. , 1998, Cellular immunology.

[16]  S. Kunkel,et al.  Chemokines in autoimmune disease. , 2001, Current opinion in immunology.

[17]  M. Arababadi,et al.  Is the CCR5 Δ 32 Mutation Associated with Immune System-Related Diseases? , 2012, Inflammation.

[18]  R. Xavier,et al.  CCR5delta32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population , 2013, Lupus.

[19]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[20]  B. Rovin,et al.  CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus , 2007, Annals of the rheumatic diseases.

[21]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[22]  C. Carcassi,et al.  Distribution of the CCR5 gene 32 base pair deletion and SDF1–3'A variant in healthy individuals from different populations , 1998, Immunogenetics.

[23]  M. Wagrowska-Danilewicz,et al.  The significant role of RANTES and CCR5 in progressive tubulointerstitial lesions in lupus nephropathy. , 2007, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[24]  K. Miura,et al.  Microarray analysis of glomerular gene expression in murine lupus nephritis. , 2008, Journal of pharmacological sciences.

[25]  J. Sánchez-Román,et al.  Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[26]  N. Shen,et al.  Current advances in the human lupus genetics , 2004, Current rheumatology reports.

[27]  K. Uhlig,et al.  Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. , 1999, Arthritis and rheumatism.

[28]  D. Gladman,et al.  Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. , 1992, The Journal of rheumatology.

[29]  L. Vilá,et al.  Association of serum MIP-1α, MIP-1β, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus , 2007, Clinical Rheumatology.

[30]  K. Matsushima,et al.  Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. , 1999, International immunology.

[31]  P. Gray,et al.  Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1β, and MIP-1α* , 1996, The Journal of Biological Chemistry.

[32]  R. D. du Bois,et al.  CC and C chemokine expression in pulmonary sarcoidosis , 2002, European Respiratory Journal.

[33]  S. Rantapää-Dahlqvist,et al.  Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus , 2003, Lupus.

[34]  C. Combadière,et al.  Role of chemokines polymorphisms in diseases. , 2012, Immunology letters.

[35]  U. Panzer,et al.  Protective role for CCR5 in murine lupus nephritis. , 2012, American journal of physiology. Renal physiology.

[36]  C. Mebus,et al.  Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial , 2012, Arthritis Research & Therapy.

[37]  H. Hashimoto,et al.  Circulating levels of beta-chemokines in systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[38]  M. Bijl,et al.  Role of CCR5 Δ32 bp deletion in RA and SLE , 2009, Autoimmunity.

[39]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[40]  S. Bombardieri,et al.  The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus , 2000, Lupus.

[41]  T. Horiuchi,et al.  Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[42]  T. Vyse,et al.  Genetic susceptibility to systemic lupus erythematosus. , 1998, Annual review of immunology.

[43]  M. Merriman,et al.  Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[44]  M. Mack,et al.  Expression of the C-C chemokine receptor 5 in human kidney diseases. , 1999, Kidney international.

[45]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[46]  K. Matsushima,et al.  Distinct Expression of CCR1 and CCR5 in Glomerular and Interstitial Lesions of Human Glomerular Diseases , 2000, American Journal of Nephrology.

[47]  C. Kallenberg,et al.  Lack of Association of C-C Chemokine Receptor 5 Δ32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity , 2010, The Journal of Rheumatology.

[48]  K. Matsushima,et al.  MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. , 1999, Kidney international.